US-based pharmaceutical major Pfizer and German biotech firm BioNTech have announced to expand the enrollment of their Phase 3 Covid-19 vaccine trial to up to approximately 44,000 participants, up from an initial recruitment goal of 30,000 individuals.
from Times of India https://ift.tt/3bQdwAU
No comments:
Post a Comment